Introduction
Apoptosis has been defined as a genetic death program that leads to ordered destruction of cellular components while it preserves membrane integrity. Most proapoptotic signaling cascades involve caspases responsible for the cleavage of death substrates (Cohen, 1997; Fischer et al., 2003) . The balance between proapoptotic and antiapoptotic signals is seemingly a prerequisite for biological homeostasis, and its disturbance may be also related to malignant transformation. Chemotherapeutic drugs and radiation therapy may activate apoptosis cascades in malignant tumors, and tumor resistance to chemotherapy is often based on a deficient apoptotic response (Helmbach et al., 2001; Kaufmann and Earnshaw, 2000; Pruschy et al., 2001; Radetzki et al., 2002; von Haefen et al., 2002) .
CD95 (Fas/APO-1)-induced apoptosis has been recognized as an important player in cell-mediated immune response (Krammer, 2000) . It is triggered by CD95 ligand (CD95L), a TNF-related type II transmembrane molecule, causing receptor oligomerization and subsequent caspase-8 activation. Caspase-8 itself may either directly cleave caspase-3 or it cleaves and activates Bid, which further delivers the signal downstream to the mitochondria. Here, the signal is amplified due to the release of proapoptotic molecules such as cytochrome c and apoptosis-inducing factor (AIF). In a complex with cytochrome c and apoptosis proteaseactivating factor (APAF-1), caspase-9 is activated and cleaves the final effector caspase-3 (Krammer, 2000; Daniel et al., 2001) . The release of cytochrome c at the mitochondrial level is controlled by the Bcl-2 protein family (Gross, 2001) .
Interestingly, death receptor signaling and anticancer drugs utilize similar signal transduction pathways to execute apoptotic cell death. This has been shown especially for caspase-8 that functions as initiator caspase in death receptor signaling but is triggered as effector caspase during drugand irradiation-induced apoptosis Engels et al., 2000; Wieder et al., 2001 ). Thus, inactivation of signaling components may lead to crosssensitization or cross-resistance not only to death receptor-triggered signals but also to anticancer therapies (Belka et al., 2001; Daniel et al., 2001) .
The question as to whether melanoma cells have acquired the ability to express CD95L and are thus able to exert a tumor counter attack against the immune system, has been discussed controversially (Hahne et al., 1996; Chappell et al., 1999) . In previous studies, we have shown that melanoma cell lines differ in their sensitivity to CD95 signals depending on the levels of Bcl-2 and Bax, regarded as critical parameters for the partial resistance of melanoma cells to CD95 signaling (Raisova et al., 2000 (Raisova et al., , 2001 .
Aim of the present investigation was to clarify the role of CD95L in melanoma and to explore the possibility of using the CD95 death pathway for therapeutic strategies in this highly malignant tumor. When screening a large series of melanoma cell lines, a vast majority revealed significant expression of CD95, but none showed any expression of CD95L. In line with this, overexpression of CD95L triggered apoptosis in melanoma cells, whereas CD95 overexpression could only sensitize cells for CD95L-induced apoptosis. These results were further confirmed in a series of animal experiments showing that expression of CD95L blocked the development and/or progression of melanoma xenotransplants in nude mice.
Results

Melanoma cell lines express CD95 but lack CD95L
For obtaining an overview about the expression of CD95 and CD95L in melanoma cells, northern blots were performed for 17 human melanoma cell lines (each independent double values) and for six independent cultures of normal human melanocytes. CD95 mRNA was identified to variable extent in all specimen (Figure 1 ). Quantification and normalization for b-actin revealed a mean expression of CD95 mRNA of 107% for melanoma cell lines, as compared to cultures of normal human melanocytes. Thus, no downregulation of CD95 mRNA was found in our series, with the exception of two melanoma cell lines (Bro and MeWo) where CD95 mRNA expression was identified at the detection limit.
On the other hand, no CD95L mRNA was detected by Northern blot analysis in any of the melanoma cell lines investigated, in full agreement with our RT-PCR-data published earlier (Raisova et al., 2000) .
In parallel to mRNA expression, most melanoma cell lines showed also significant surface expression of CD95 as determined by FACS analysis (Figure 2 ). Surface expression was also analysed in three independent cultures of normal human melanocytes to prove whether CD95 might be downregulated in melanoma cells. The level of CD95 surface expression in melanoma cell lines was, however, comparable to that of the melanocyte cultures, with the exception of cell lines Bro and MeWo, Figure 1 Expression of CD95 mRNA in melanoma cells. The expression of CD95 mRNA as determined by Northern blotting is shown for four cultures of normal human melanocytes (NHM) and for 17 human melanoma cell lines. The control hybridization with b-actin is shown below. Hybridization with the CD95 probe resulted in two mRNAs of 2700 and 1900 nucleotides, respectively. The experiment was repeated once with a set of independently prepared mRNAs and showed a comparable result Figure 2 Comparably high CD95 surface expression in melanoma cell lines and in cultured normal melanocytes. CD95 surface expression as determined by FACS analysis of melanoma cell lines and cultures of normal human melanocytes is shown. Cells were labeled with a specific CD95 antibody (filled graphs) and with an isotypic control antibody (open graphs), respectively. For each cell line double experiments from independent cultures had been performed, and double values were always similar. Comparably high CD95 surface expression is seen in normal human melanocytes (NHM) and in melanoma cell lines with the exception of cell lines MeWo and Bro. CD95 surface expression in two tetracyclineregulatable cell lines investigated in parallel (SKM-13-Tet-On and Mel-2a-Tet-Off, see the following paragraph) was equivalent to that of the parental cell lines (SK-Mel-13 and Mel-2a) CD95/Fas signaling in melanoma J Eberle et al which had been also characterized by weak mRNA expression ( Figure 1 ). Thus, also from the surface expression data there was no indication for CD95 downregulation in the majority of melanoma cell lines.
Conditional expression of CD95L but not of CD95 triggers apoptosis in transfected melanoma cell lines
In order to prove whether apoptosis can be triggered in melanoma cells by activation of the CD95 signaling cascade, CD95 and CD95L were transfected in melanoma cell lines and the result on apoptosis was determined.
In applying the tetracycline-regulatable gene expression system (Gossen and Bujard, 1992) (Figure 3a) . In Mel2a-Tet-Off and SKM13-Tet-On apoptosis was increased after CD95L transfection by 11.670.2-and 5.170.1-fold, respectively, as compared to vector (pTRE) transfection (Figure 3b, c) . Surprisingly also Bro-Tet-On (1.770.05-fold) and MeWo-Tet-On (2.170.2-fold; Figure 3d , e) showed some induction of apoptosis after CD95L transfection, although characterized by only weak and hardly detectable expression of CD95 (Figures 1 and 2 ). This may be seen as an indication that already extremely weak CD95 expression allows CD95-mediated apoptosis in melanoma cells. As an additional control, a CD95L cDNA that lacked the ATG was generated by deletion of 20 nucleotides (CD95LD); again, apoptosis after CD95LD transfection was found close to background levels, thus underlining the specific proapoptotic effect of CD95L overexpression in all four cell lines ( Figure  3b -e). The proapoptotic effect of CD95L transfection was further confirmed by analysis of caspase-3 activity, which was significantly enhanced (data not shown).
Due to the leakiness of the tetracycline promoter, apoptosis after CD95L transfection was detected at relatively high levels also under noninducing conditions. However, significant regulation of apoptosis by doxycycline was seen in SKM13-Tet-On and in Mel2a-Tet-Off after transient transfection of only 5% of the CD95L plasmid routinely employed in other transfection experiments (Figure 3f ). Overexpression of CD95 and CD95L proteins was also monitored by Western blot analysis and resulted in specific protein bands of 41 kDa (CD95L) and 42 kDa (CD95), as shown in Figure 4 . Activity of overexpressed CD95 receptor was further investigated by monitoring the cellular response to an agonistic CD95 antibody (CH-11). After transient CD95 transfection, doxycycline-mediated induction of CD95 enhanced the sensitivity of SKM13-Tet-On cells for CH-11, whereas, sensitivity was reduced by doxycyclinemediated suppression of CD95 expression in Mel2a-TetOff cells, indicating that CD95L sensitivity of melanoma cells can be further increased to some extent by CD95 overexpression ( Figure 5 ).
For further investigating the proapoptotic effect of CD95L, stable cell clones of SKM13-Tet-On transfected with CD95L cDNA were generated. Isolated cell clones were characterized by doxycycline inducibility of a 1650 bp CD95L-specific mRNA (Figure 6a ), and apoptosis was triggered by the addition of doxycycline between 1.370.1-and 2.470.6-fold (Figure 6b ). The parental cell line SKM13-Tet-On neither showed CD95L mRNA nor apoptosis inducibility after doxycycline treatment (data not shown). Clone 503B4 showing the highest inducibility of apoptosis was selected for subsequent experiments (SKM13-CD95L).
After CD95L mRNA induction, the downstream signaling cascade was studied by Western blot analysis: CD95L protein was clearly detectable at 24 h after onset of doxycycline induction and was further increased at 48 h. In parallel, procaspase-3, Bid and procaspase-8 levels were decreased, clearly indicating caspase activation and involvement of these proteins in establishing apoptosis after induction of CD95L ( Figure 7a ). In line with this, cleavage products of caspase-8 with 43, 41 and 18 kDa were detected ( Figure 7b ) and caspase-3 activity was found to be increased after CD95L induction ( Figure 7c ). Cytosolic release of cytochrome c and of AIF ( Figure 7d ) as well as PARP cleavage (data not shown) were also detected after CD95L induction.
In order to prove our hypothesis that death ligands may be used to overcome mitochondrial apoptosis resistance we investigated whether the proapoptotic activity of chemotherapeutic drugs, etoposide/VP-16 (0.3 mM), cisplatin (5 mM) and doxorubicin (0.2 mM), may be enhanced by CD95L induction in stably transfected SKM-13-CD95L cells. Whereas SKM-13-Tet-On parental cells were largely apoptosis resistant when stimulated with these chemotherapeutic drugs, SKM-13-CD95L cells represented a significantly higher sensitivity to cisplatin and doxorubicin, even before induction of CD95L, which may possibly be due to leaky expression from the tetracycline-responsive promoter (see above). The apoptotic response to all three chemotherapeutics was significantly further enhanced after induction of CD95L by doxycycline in SKM-13-CD95L cells (Figure 8 ).
Conditional CD95L expression completely blocks the growth of human melanoma xenotransplants in nude mice
For assessing the antitumor potential of CD95L in vivo, a total of 21 nude mice were subcutaneously injected with SKM13-CD95L-transfected cells into both flanks. For promoter induction, seven animals received CD95/Fas signaling in melanoma J Eberle et al doxycycline with the drinking water beginning with day 3 after tumor cell inoculation; a further seven animals received doxycycline beginning only with day 30 after inoculation when small subcutaneous melanomas had already developed. A control group of seven animals did not receive any doxycycline for the entire period of observation.
After 4 weeks, tumors were found in untreated animals at most injection sites and after 8 weeks at all 14 injection sites. In clear contrast, no tumor was seen in the doxycycline-treated animals until week 12 ( Figure 9 ). In the follow-up period between days 30 and 61 the tumor volumes increased exponentially by 31-fold in the untreated mice, whereas in animals receiving doxycycline after day 30 the tumor mass increased only 3.4-fold. Four animals of this group showed stable tumor masses during 4 weeks after the onset of treatment and also tumor regression zones were clearly recognizable at several injection sites ( Figure 9 ). As additional controls, four animals were injected with the parental cell line SKM-13-Tet-On and another four with vector-transfected SKM-13-Tet-On cells. In these control animals tumors developed at all injection sites until week 12, irrespectively of doxycycline treatment (data not shown).
Culture supernatant of CD95L-transfected melanoma cells induces apoptosis
In further experiments the question was addressed, whether CD95L-transfected melanoma cells may also induce apoptosis in neighboring untransfected cells, thus causing a bystander effect required for anti-cancer therapy in vivo. Culture supernatants of SKM13-CD95L cells grown with and without doxycycline induction, were cleared by centrifugation and were added to the parental cells (SKM13-Tet-On) as well as to noninduced SKM13-CD95L cells. After 2 days, the supernatant from induced SKM13-CD95L cells strongly induced apoptosis in both recipient cell lines as compared to untreated cells, whereas supernatant from noninduced SKM13-CD95L cells was much less effective ( Figure 10 ).
Discussion
CD95L is a key effector molecule of cytotoxic T lymphocytes and thus fundamental in the immune response against tumor cells (Nagata and Golstein, 1995) . On the other hand, it has been postulated that certain tumors may use CD95 signaling to acquire an immune-privileged state by expressing CD95L and in parallel downregulating the receptor (O'Connell et al., 1996) . This tumor counter attack hypothesis has been discussed controversially for melanoma, and the question as to whether melanoma cells are able to express CD95L remained under debate (Hahne et al., 1996; Chappell et al., 1999; Aragane et al., 2000; Andreola et al., 2002; Bullani et al., 2002; Redondo et al., 2002; Ivanov et al., 2003) . Some of the positive findings of CD95L expression in melanoma may also be due to unspecific binding in Western blots and immunohistochemistry reported for several CD95L antibodies (Strater et al., 2001) . The outcome of this discussion may have fundamental consequences when thinking of a CD95-based therapeutic approach (Timmer et al., 2002) , since CD95L-expressing cells that have downregulated CD95 could be targeted by overexpression of the receptor rather than of the ligand. To better understand the significance of the CD95 death pathway for melanoma, we investigated the expression pattern of CD95 receptor and ligand as well as their functional relevance for induction of apoptosis and tumorigenic growth in melanoma cells. In our series, no CD95L mRNA expression was detectable in any of 17 human melanoma cell lines screened, whereas CD95 mRNA and surface expression were found at significant levels both in normal human melanocytes and in the melanoma cell lines studied. In particular, no downregulation of CD95 was seen in melanoma cells neither at the mRNA nor surface expression level.
In a recent paper, we had screened melanoma cell lines used also in the present study for their susceptability for CD95 ligation by agonistic antibodies (Raisova et al., 2000) . These susceptability data, however, did not reveal a clear-cut correlation to the expression data obtained here, although, melanoma cell susceptability was found significantly enhanced after transient overexpression of CD95 in the present study. Therefore, CD95 expression levels do not seem to be the final regulator for CD95L sensitivity but may play a supportive role in enhancing cellular sensitivity to apoptosis.
According to the tumor counter attack model, CD95 would act as tumor suppressor and induction of apoptosis may follow CD95 overexpression (Aragane et al., 2000; Muschen et al., 2000) . In our studies, however, no apoptosis induction after CD95 overexpression was seen in four melanoma cell lines investigated. Overexpression was undoubtedly confirmed by Western blot analyses as well as by functional assays.
In clear contrast to the findings with CD95, apoptosis was strongly induced in melanoma cells after transfection of CD95L, clearly indicating a functional CD95-dependent signaling cascade in melanoma cells. Interestingly, also melanoma cell lines found by us to be resistant to the agonistic CD95 antibody CH-11 (Raisova et al., 2000) responded with increased apoptosis after CD95L transfection. A gene dosis effect may be ruled out, as even the 20-fold reduced amount of plasmid DNA used for transfection showed strong proapoptotic effects. The difference may be rather due to variant activities reported for agonistic antibodies as compared with natural, membrane-bound CD95L (Sieg et al., 1999) . The reproducible sensitivity of melanoma cells to CD95L transfection appears attractive when considering a possible use in gene therapy approaches.
The applicability of the CD95 system to inhibit cancer growth and invasion has been demonstrated earlier by agonistic antibodies applied in mice (Trauth et al., 1989; Dhein et al., 1992; Coney et al., 1994) , although considerable systemic toxicity, in particular hepatotoxicity was reported (Ogasawara et al., 1993) . Side effects result from the fact that a broad variety of nonmalignant cells are susceptible to CD95-triggered apoptosis. CD95 activation may also lead to immune suppression, since physiological signaling via CD95 is involved in immune tolerance both of T and B cells . In this regard the present paper may at first be seen as proof of principle that death ligands may kill tumor cells even when other apoptotic pathways are blocked. On the other hand, the side effects reported for CD95 antibodies may primarily arise from the systemic approach, by which various CD95-positive populations are targeted rather unspecifically. Gene transfer techniques may allow to restrict apoptosis induction to the cells targeted by the vector applied. Furthermore, selective expression of transgenes in melanomas may be achieved by applying pigmentation gene promoters for which tight downregulation has been demonstrated in cells noninvolved in melanin synthesis (Park et al., 1999) .
Antitumor activity of CD95L gene transfer has already been demonstrated in animal models for prostate cancer (Hedlund et al., 1999) , glioma (Ambar et al., 1999; Shinoura et al., 2000) , insulinoma (Okamoto et al., 1999) and renal epithelial carcinoma (Arai et al., 1997) . CD95L-induced apoptosis may be further enhanced by the combination with other proapoptotic genes, p.e. p53, also a known inducer of CD95 receptor gene expression (Shinoura et al., 2000) . For melanoma, there were no reports by now on similar gene transfer experiments with CD95L. The applicability of a CD95L-based antitumor strategy against melanoma is strongly supported by the data obtained in our xenotransplant model. The conditional expression of CD95L completely prevented tumorigenic growth. Likewise, the growth of established tumors was inhibited when CD95L expression was turned on at later time points. The antitumor activity may be further supported by infiltrating neutrophils attracted by CD95L (Seino et al., 1997; Behrens et al., 2001 ), however, due to the strong proapoptotic effect we found in melanoma cells When thinking of gene therapy approaches based on viral vectors, elimination of neighboring, not infected tumor cells is a prerequisite. A soluble form of CD95L can be generated by metalloprotease cleavage (Mariani et al., 1995) , but both proapoptotic and inhibitory effects have been described for soluble CD95L (Suda et al., 1997) , partly controlled by accessory molecules (Sieg et al., 1999) . In the present investigation we found a strong proapoptotic effect deriving from the supernatants of CD95L-transfected cells on recipient melanoma cells indicating melanoma cell sensitivity to the soluble ligand. Soluble CD95L would confer the capacity in a therapeutic approach to induce apoptosis in surrounding untransfected melanoma cells. In summary, our data do not support the hypothesis of a tumor counter attack due to CD95L expression in human melanoma cells; rather we present conclusive evidence that forced expression of CD95L induces apoptosis in melanoma cells proving that receptormediated apoptosis pathways remain intact. Finally, conditional expression of CD95L prevented melanoma tumor formation and progression of established tumors xenotransplanted in nude mice. It appears therefore conceivable to employ the CD95L gene as an effective tool for antimelanoma strategies, possibly in combination with chemotherapeutic drugs. Severe side effects reported for systemic treatment with CD95 agonistic antibodies may be at least partly overcome by applying transcriptional targeting for in vivo gene transfer.
Materials and methods
Cell culture and RNA extraction
Normal human melanocytes were isolated from human foreskins after trypsin digestion (Eisinger and Marco, 1982) and were cultured serumfree as previously described (Eberle et al., 1995) . Four human melanoma cell lines were used for gene transfection: Bro (Lockshin et al., 1985) , Mel-2a (Bruggen et al., 1981) , MeWo (Bean et al., 1975) and SK-Mel-13 (Carey et al., 1976) . A reference list for melanoma cell lines A-375, IGR-37, IGR-39, JPC-298, M-5, Mel-57, Mel-HO Mel-JUSO, NKI-4, O-mel-2, SK-Mel-19, SK-MEL-23, SK-Mel-28 used for Northern blotting and FACS analysis was given in previous publications (Eberle et al., 1995; Raisova et al., 2000) . Cell lines were maintained in DMEM (4.5 g/l glucose; Gibco) supplemented with 10% fetal calf serum and antibiotics (Biochrom).
For apoptosis induction, chemotherapeutics were added to the growth medium 24 h before determination of apoptotic rates and cytotoxicity: etoposide/VP-16 (Sigma-Aldrich, Taufkirchen, Germany; 0.3 mM), cisplatin (Sigma-Aldrich; 5 mM), and doxorubicin (QBiogene-Alexis, Gru¨nberg, Germany; 0.2 mM). The agonistic anti-CD95 antibody CH-11 (IgM mouse; Beckman Coulter, Krefeld, Germany) was applied for 16 h in a concentration of 0.5 mg/ml.
Plasmid constructs
A murine full-length cDNA fragment of CD95L (nucleotides 31-870, according to the sequence described by Lynch et al., 1994) was subcloned into the SstII and EcoRI restriction sites of the tetracycline-inducible vector pTRE-1 (Clontech, Palo Alto, CA, USA). As a control, a deletion clone of CD95L lacking 20 nucleotides surrounding the ATG was generated by fusion of the internal BglII site (position 62) with an external (pBluescript) BamHI site, and it was further subcloned into SstII and EcoRI sites of pTRE-1 (CD95LD). A human CD95 cDNA fragment (nucleotides 150-1840, according to the sequence described by Oehm et al., 1992) was subcloned into the SacII and EcoRI sites of pTRE-1.
Expression analyses
For mRNA expression analysis, total RNA was isolated during logarithmic growth phase (RNeasy; Qiagen, Hilden, Germany), 24 h after applying fresh growth medium. For Northern blotting, 30 mg of total RNA were separated per lane in formaldehyde/1.2% agarose gels. Blotting and hybridizations were carried out as described previously (Eberle et al., 1995) . As probes, full-length cDNA fragments of mouse CD95 and CD95L were used; the probe for b-actin originated from a melanoma cell cDNA library (Eberle et al., 1995) . For quantification, a BAS-1500 Phosphoimager (Fuji, Nakanuma, Japan) was used. For normalization, membranes were rehybridized with the probe for b-actin.
For analysis of CD95 surface expression, cells were harvested from culture plates by treatment with 0.02% EDTA in PBS. After washing with PBS, aliquots of 1 Â 10 6 cells in 100 ml PBS, 1% BSA were incubated for 30 min either with phycoerythrin (PE)-labeled monoclonal anti-CD95 antibody (clone DX2) or with an isotypic PE-labeled IgG 1 ,k monoclonal control antibody (clone MOPC-21, both antibodies from Becton Dickinson, Heidelberg, Germany), as recommended by the manufacturer. After washing with PBS, CD95 surface expression was determined with a FACSCalibur TM flow cytometer (Becton Dickinson). The mean fluorescence index was calculated using CellQuest TM software (Becton Dickinson).
Cell transfection
Melanoma cells were seeded in six-well plates with 2 Â 10 5 cells/well. For transient cell transfections, cells at a confluence of 50% were washed with serum-free Opti-MEM medium (Life Technologies) followed by incubation with 0.1% DMRIE-C (Life Technologies) and 0.4 mg/ml plasmid DNA at 371C in Opti-MEM for 4 h. For stable cell transfections, cells were incubated with 0.5% Pfx-2 (Invitrogen, Groningen, Netherlands) and 1.5 mg/ml plasmid DNA at 371C for 2 h. For selection of transfected clones, geneticin (Life Technologies; 400 mg/ml) and hygromycin (Boehringer, Mannheim, Germany; 100 mg/ml) were used. Cell clones were obtained by limited dilution in microtiter plates and were continuously cultured in presence of antibiotics.
Conditional gene expression
The tetracycline-regulatable gene expression system had been described by Gossen and Bujard (1992) . SKM13-Tet-On, BroTet-On, MeWo-Tet-On and Mel2a-Tet-Off cell lines were derived from melanoma cell lines SK-Mel-13, Bro, MeWo and Mel-2a by stable transfection of pTet-On and pTet-Off plasmids, respectively (Clontech). Bro-Tet-On and SKM13-Tet-On cell lines had already been described in a previous paper (Eberle et al., 2002) . For pTRE promoter activation (Tet-On cell lines) or repression (Mel2a-Tet-Off), 2 mg/ml doxycycline (ICN, Aurora, OH, USA) were added to the growth medium instead of tetracycline (Gossen and Bujard, 1992) . Doxycycline inducibility was quantified in individual cell clones after transient transfection of the luciferaseencoding plasmid pTRE-Luc (Clontech) followed by a luciferase assay (Promega, Madison, WI, USA), 48 h later. Double stable transfected cells were obtained by cotransfection of pTRE-CD95L and the hygromycin resistance plasmid pTKHyg (Clontech; 1 : 20 molar ratio) in SKM13-Tet-On.
Quantification of apoptosis
Doxycycline was added directly after transient transfection, and apoptosis was quantified after 48 h by using a cell death detection ELISA (Roche Diagnostics), which detects monoand oligonucleosomes formed in apoptotic cells. A detailed protocol has been described by us previously (Wieder et al., 1998) . Double stable transfected cell clones at a confluence of 50% were also treated with doxycycline for 48 h, before apoptosis was quantified. Relative apoptotic rates were CD95/Fas signaling in melanoma J Eberle et al calculated either by comparison with vector (pTRE) transfections or as the ratio between doxycycline-induced and noninduced cells. To demonstrate statistical significance of apoptosis assays, students t-test was applied (unpaired and heteroscedastic).
For a caspase-3 activity assay (Calbiochem), protein extracts were made from cells grown in six-well plates at a confluence of 50-70%. Protein concentrations were determined with BCA protein assay reagent (Pierce, St Augustin, Germany), and assays were performed with 100 mg protein according to the protocol of the supplier.
Western blot analysis
For protein extraction, cells were harvested by trypsinization at a confluence of 60-80% and were lysed in the respective lysis buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 100 mM PMSF, 1 mM leupeptin, 1 mM pepstatin, 0.1% SDS, 0.5% sodiumdeoxycholate, 1% Triton X-100 (for analysis of CD95, Bid, procaspase-3 and procaspase-8); 50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM PMSF, 2 mM leupeptin, 1.4 mM pepstatin, 0.1% SDS, 1% Triton X-100 (for CD95L); and 62.5 mM Tris/HCl, pH 6.8, 6 M urea, 10% glycerol, 2% SDS, 5% b-mercaptoethanol (for analysis of PARP and caspase-8 cleavage products). For determination of cytochrome c and AIF release, cytosolic and mitochondrial proteins were fractionated by a mitochondria/cytosol fractionation kit (Alexis, Gru¨nberg; Germany).
For Western blotting, cell suspensions were homogenized and centrifuged for 5 min at 10 000 g. Each 50 mg were separated by electrophoresis under reducing conditions on 7-15% SDS-polyacrylamide gels (PAGE) in parallel with a broad range prestained SDS-PAGE protein standard (BioRad, Mu¨nchen, Germany). Proteins were transferred by electroblotting to Protran BA85 nitrocellulose membranes (Schleicher & Schu¨ll, Dassel, Germany) . Blots were blocked overnight with PBS, 0.05% Tween, 3% nonfat dry milk and incubated with the respective antibodies diluted in blocking buffer. After washing with 0.05% Tween-20 in PBS or TBS, blots were incubated in peroxidase-labeled anti-rabbit, antigoat or anti-mouse IgG (Dako, Hamburg, Germany) diluted 1 : 5000 in blocking buffer. After washing with 0.05% Tween-20, specific binding of antibodies was detected by chemiluminescence using ECL-Western blotting detection reagents (Amersham Pharmacia Biotech, Freiburg, Germany) on Hyperfilm ECL (Amersham Pharmacia Biotech).
The following antibodies were used: CD95: rabbit polyclonal IgG (N-18, sc-714, Santa Cruz, Heidelberg, Germany, 1 : 1000); CD95L: rabbit polyclonal IgG (N-20, sc-834, Santa Cruz, 1 : 200); Bid: goat polyclonal IgG (N-19, sc-6539, Santa Cruz, 1 : 200); caspase-3: rabbit polyclonal IgG (Pharmingen, 556425; BD Biosciences, Heidelberg, Germany, 1 : 200); PARP: mouse monoclonal (Mol-Biol, Hamburg, Germany, 1 : 1000); cytochrome c: mouse monoclonal (Pharmingen, Heidelberg, Germany, 1 : 800); a caspase-8 antiserum was kindly supplied by K Schulze-Osthoff (Department for Molecular Medicine, Heinrich Heine University Du¨sseldorf, Germany).
Mouse experiments
Melanoma cells were harvested by brief incubation with trypsin/EDTA, and trypsin was subsequently inactivated by washing cells twice with growth medium containing 10% FCS. Before inoculation, cells were washed with PBS and were finally resuspended in PBS in a concentration of 10 6 cells/ 200 ml. Female 6-8 weeks old Balb C-nu/nu mice (M&B A/S, Ry, Denmark) received s.c. injections of each 10 6 cells (200 ml) into both flanks. For induction of the tetracycline-responsive promoter, animals received doxycycline with the drinking water (2 mg/ml enriched with 50 mg/ml sucrose), whereas control mice received only sucrose-enriched water. After tumors became visible, mice were seen twice a week, body weight was determined, tumor size was measured and tumor volume was calculated. Animal experiments were performed according to the guidelines of the Federation of European Laboratory Animal Sciences Associations (FELASA).
